lithium carbonate + selective serotonin reuptake inhibitor + venlafaxine

This drug is a combination therapy comprising **lithium carbonate**, **venlafaxine**, and an unspecified **selective serotonin reuptake inhibitor (SSRI)**. Lithium carbonate is a mood stabilizer approved for the treatment and prevention of manic episodes associated with bipolar disorder. Venlafaxine is a serotonin-norepinephrine reuptake inhibitor (SNRI) indicated for major depressive disorder, generalized anxiety disorder, social anxiety disorder, and panic disorder. SSRIs are a class of antidepressants that increase serotonin levels in the brain by selectively inhibiting its reuptake. The rationale for combining these medications is to target treatment-resistant depression or bipolar depression, though such combinations carry an increased risk of adverse effects such as serotonin syndrome and require vigilant monitoring. When administered together, lithium may alter the pharmacokinetics of venlafaxine and SSRIs, but studies indicate no major clinically significant pharmacokinetic interactions between venlafaxine and lithium. However, there is published evidence of increased risk of serotonin syndrome when lithium is used concomitantly with serotonergic antidepressants[1][2][3][4][5].